As a result of alternative splicing, ZMYND8 exon 22 inclusion was linked to a better prognosis in breast cancer patients, enhanced by hnRNPM and opposed by Epithelial Splicing Regulatory Protein 1 (ESRP1) [34]. This evidence concerns the gene ESRP1 and breast carcinoma.